Molecular PD-L1 PET/CT Imaging with 89Zr-atezolizumab to Monitor Immune Responses in metastatic Triple Negative Breast Cancer: study protocol for a phase II diagnostic imaging trial

Renske Altena, Thuy A. Tran, Una Kjällquist, Mattias Karlsson, Jonathan Siikanen, Emma Jussing, Antonios Tzortzakakis, Olof Jonmarker, Rimma Axelsson, Jonas Bergh
doi: https://doi.org/10.1101/2023.03.13.23287203

Data Availability

This is a manuscript presenting a study protocol without preliminary data and therefore, this is not applicable here.

Back to top
Posted March 14, 2023.
Download PDF
Data/Code
Email
Molecular PD-L1 PET/CT Imaging with 89Zr-atezolizumab to Monitor Immune Responses in metastatic Triple Negative Breast Cancer: study protocol for a phase II diagnostic imaging trial
Renske Altena, Thuy A. Tran, Una Kjällquist, Mattias Karlsson, Jonathan Siikanen, Emma Jussing, Antonios Tzortzakakis, Olof Jonmarker, Rimma Axelsson, Jonas Bergh
medRxiv 2023.03.13.23287203; doi: https://doi.org/10.1101/2023.03.13.23287203
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area